Default company panoramic image
B2caa8e1 5751 4a81 9df9 e025b8872ae7

WBC Labs

White Blood Cells (WBCs) are essential. The market for WBC stimulating drugs is $8B/yr. WBC Labs has the next generation of WBC drugs.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Aurora, CO, USA
  • Currency USD
  • Founded May 2012
  • Employees 2

Company Summary

WBCs stimulants are used in patients after chemotherapy or before transplant. Nevertheless patients too often develop infections, fevers or even fatal sepsis. The drugs from WBC Labs are conservatively targeted to increase the effectiveness of current drugs but should, in many cases, replace them. In addition there is major government interest in stockpiling WBC stimulating drugs to protect the public from biologic and radiation attack.

Team

  • Default avatar
    Tom Perun, Ph.D.
    Advisor

    He retired after 30 years at Abbott most recently as VP of Drug Design & Delivery. He received his B.S. from Rensselear Polytechnic Institute, his M.B.A from Lake Forest and his Ph.D. from the University of Rochester. He is a past Chair and Councilor for the Medicinal Chemistry Division of the American Chemical Society. He pioneered rational drug design and edited Computer-Aided Drug Design: Methods and Applications.

  • Default avatar
    Floyd Elliot Taub
    Chairman, CEO

    Past CEO of: CytoCore, Inc. (CYOE); LifeTime Pharmaceuticals, Inc., which developed a WBC drug that shrank cancer shrinkage without toxicity; FindCure.Org, Inc, a 501(c)3, and Digene, the HPV company. He was CMO of Otraces, Inc., and Eveia Medical, Inc. He headed a Pathology Unit NIH. His M.D. is from the Northwestern University; pathology at the UC, Fellowship at George Washington University. He is “Board Certified” in pathology and licensed in

  • Default avatar
    Robert Hodges, Ph.D.
    Chief Scientific Advisor

    He is the John Stewart Professor UC and Head of the Peptide Core UC, AMC.

    He has an excellent record of NIH funded research projects involving creation of peptide drugs. Awards include the Distinguished MRC Scientist Award, the Boehringer-Mannheim Award, and the Vincent du Vignead Award from the American Peptide Society. He has been President and CEO, Director over 500 publications and 48 patents.

  • Default avatar
    Dwight Zurawski
    Advisor

    Was Controller for McKinley Medical, a $20 million international infusion pump company. From 1996-2000, he was President of Tissue Medical Lasers, a $16 million dermatological laser manufacturer and was CFO for a division of Palomar Medical Tech, a NASDAQ medical device manufacturer. He acquired tax and auditing expertise with KPMG. He is a graduate of the University Of New Mexico Anderson School Of Business and has been a CPA since 1977.

  • Default avatar
    Richard , Ph.D. Duke
    Advisor

    Has nearly 20 years building, financing, and managing start-ups He is CSO of CID4. His companies include GlobeImmune; Newellink/Viral Genetics, Inc.; ApopLogic Pharmaceuticals; Sierra Neuropharmaceuticals/ICVRx, Inc.); MenoGeniX; PeptiVir; and Aurora Oncology. He filed several INDs and had 4 products in Phase I/II. He has been a P.I. on $10 MM in grants and is tenured at CU. His B.Sc. and M.Sc. is from McGill and his Ph.D. from the UC.

  • Default avatar
    Jeff Rona, B.S.
    Acting CFO

    Mr. Rona has completed transactions, including multiple licenses and an IPO, totaling in excess of $500 million. His work included multiple rounds of public and private equity and two liquidity events and several licensing agreements. His companies include GlobeImmune, Inc., Celgene, Inc. AlgoRx Pharmaceuticals, Corgentech and Antigenics. As an investment banker, he was involved in the execution of over $2 billion He has a B.S. in Accounting fro